Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data

Experimental Eye Research

Volumn 137, Issue , 2015, Pages 111-124

  del Amo, Eva M ^a,b   Urtti, Arto ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Animal model; Drug delivery; Intravitreal; Ocular pharmacokinetics; Rabbit

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GENTAMICIN; VANCOMYCIN;

ANIMAL MODEL; AQUEOUS HUMOR; AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; ELIMINATION RATE CONSTANT; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RABBIT; REVIEW; STUDY DESIGN; VOLUME OF DISTRIBUTION; ANIMAL; CHEMISTRY; DISEASE MODEL; METABOLISM; PUBLICATION; RETINAL DISEASES; STANDARDS; VITREOUS BODY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; PERIODICALS AS TOPIC; RABBITS; RETINAL DISEASES; VITREOUS BODY;

EID: 84938213842     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2015.05.003     Document Type: Review

References (102)

1. Ahn J., Kim H., Woo S.J., Park J.H., Park S., Hwang D.J., Park K.H. Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J.Ocul. Pharmacol. Ther. 2013, 29:612-618.
2. Ahn S.J., Ahn J., Park S., Kim H., Hwang D.J., Park J.H., Park J.Y., Chung J.Y., Park K.H., Woo S.J. Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 2014, 55:567-573.
3. Alm A., Bill A. Ocular and optic nerve blood flow at normal and increased intraocular pressures in monkeys (Macaca irus): a study with radioactively labelled microspheres including flow determinations in brain and some other tissues. Exp. Eye Res. 1973, 15:15-29.
4. Atluri H., Mitra A.K. Disposition of short-chain aliphatic alcohols in rabbit vitreous by ocular microdialysis. Exp. Eye Res. 2003, 76:315-320.
5. Bakri S.J., Snyder M.R., Reid J.M., Pulido J.S., Singh R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007, 114:855-859.
6. Barany Y.E., Kinsey V.E. The rate of flow of aqueous humor; the rate of disappearance of para-aminohippuric acid, radioactive rayopake, and radioactive diodrast from the aqueous humor of rabbits. Am. J. Ophthalmol 1949, 32:177-188. Pt. 2.
7. Bashshur Z.F., Haddad Z.A., Schakal A., Jaafar R.F., Saab M., Noureddin B.N. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am. J. Ophthalmol. 2008, 145:249-256. e2.
8. Beer P.M., Wong S.J., Hammad A.M., Falk N.S., O'Malley M.R., Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 2006, 26:871-876.
9. Bejanian M., Lieberman R.M., Goldstein D.A., Engstrom R.E., Boyer D.S., Dunn J.P. Apharmacokinetic study of intravitreal fomivirsen in patients with CMVR. Invest. Opthalmol. Vis. Sci. 1999, 40. S874-Abstract.
10. Brubaker R.F. The flow of aqueous humor in the human eye. Trans. Am. Ophthalmol. Soc. 1982, 80:391-474.
11. Cheung L.K., Eaton A. Age-related macular degeneration. Pharmacotherapy 2013, 33:838-855.
12. Chen X., Hickling T., Kraynov E., Kuang B., Parng C., Vicini P. Amathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics. AAPS J. 2013, 15:1141-1154.
13. Chin H.S., Park T.S., Moon Y.S., Oh J.H. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 2005, 25:556-560.
14. Christoforidis J.B., Carlton M.M., Knopp M.V., Hinkle G.H. PET/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. Invest. Ophthalmol. Vis. Sci. 2011, 52:5899-5903.
15. Christoforidis J.B., Williams M.M., Kothandaraman S., Kumar K., Epitropoulos F.J., Knopp M.V. Pharmacokinetic properties of intravitreal i-124-aflibercept in a rabbit model using PET/CT. Curr. Eye Res. 2012, 37:1171-1174.
16. Christoforidis J.B., Williams M.M., Wang J., Jiang A., Pratt C., Abdel-Rasoul M., Hinkle G.H., Knopp M.V. Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy. Retina 2013, 33:946-952.
17. Dejneka N.S., Wan S., Bond O.S., Kornbrust D.J., Reich S.J. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol. Vis. 2008, 14:997-1005.
18. del Amo E.M., Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today 2008, 13:135-143.
19. del Amo E.M., Vellonen K., Kidron H., Urtti A. Intravitreal clearance and volume of distribution of compounds in rabbits: In silico prediction and pharmacokinetic simulations for drug development. Eur. J. Pharm. Biopharm. 2015, 10.1016/j.ejpb.2015.01.003.
20. Diaz-Llopis M., Chipont E., Sanchez S., Espana E., Navea A., Menezo J.L. Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. Am. J. Ophthalmol. 1992, 114:742-747.
21. Doft B.H., Weiskopf J., Nilsson-Ehle I., Wingard L.B. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology 1985, 92:1601-1605.
22. Durairaj C., Kim S.J., Edelhauser H.F., Shah J.C., Kompella U.B. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest. Ophthalmol. Vis. Sci. 2009, 50:4887-4897.
23. Duvvuri S., Gandhi M.D., Mitra A.K. Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. Curr. Eye Res. 2003, 27:345-353.
24. Eyetech Study Group Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002, 22:143-152.
25. Ezan E. Pharmacokinetic studies of protein drugs: past, present and future. Adv. Drug Deliv. Rev. 2013, 65:1065-1073.
26. Feke G.T., Tagawa H., Deupree D.M., Goger D.G., Sebag J., Weiter J.J. Blood flow in the normal human retina. Invest. Ophthalmol. Vis. Sci. 1989, 30:58-65.
27. Ferencz J.R., Assia E.I., Diamantstein L., Rubinstein E. Vancomycin concentration in the vitreous after intravenous and intravitreal administration for postoperative endophthalmitis. Arch. Ophthalmol. 1999, 117:1023-1027.
28. Ficker L., Meredith T.A., Gardner S., Wilson L.A. Cefazolin levels after intravitreal injection. Effects of inflammation and surgery. Invest. Ophthalmol. Vis. Sci. 1990, 31:502-505.
29. Gajraj R.T.C. AStudy of Drug Transport in the Vitreous Humor: Effect of Drug Size; Comparing Micro- and Macro-scale Diffusion; Assessing Vitreous Models; and Obtaining inVivo Data 2012, https://tspace.library.utoronto.ca/handle/1807/33202.
30. Gan I.M., Ugahary L.C., van Dissel J.T., van Meurs J.C. Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. Graefes Arch. Clin. Exp. Ophthalmol. 2005, 243:1186-1189.
31. Gan I.M., van Dissel J.T., Beekhuis W.H., Swart W., van Meurs J.C. Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis. Br. J. Ophthalmol. 2001, 85:1289-1293.
32. Gaudreault J., Fei D., Beyer J.C., Ryan A., Rangell L., Shiu V., Damico L.A. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007, 27:1260-1266.
33. Gillette J.R. Factors affecting drug metabolism. Ann. N. Y. Acad. Sci. 1971, 179:43-66.
34. Gupta S.K., Velpandian T., Dhingra N., Jaiswal J. Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. J.Ocul. Pharmacol. Ther. 2000, 16:511-518.
35. Haider S.A., Hassett P., Bron A.J. Intraocular vancomycin levels after intravitreal injection in post cataract extraction endophthalmitis. Retina 2001, 21:210-213.
36. Hemenger R.P., Garner L.F., Ooi C.S. Change with age of the refractive index gradient of the human ocular lens. Invest. Ophthalmol. Vis. Sci. 1995, 36:703-707.
37. Henry K., Cantrill H., Fletcher C., Chinnock B.J., Balfour H.H. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am. J. Ophthalmol. 1987, 103:17-23.
38. Hughes P.M., Krishnamoorthy R., Mitra A.K. Vitreous disposition of two acycloguanosine antivirals in the albino and pigmented rabbit models: a novel ocular microdialysis technique. J.Ocul. Pharmacol. Ther. 1996, 12:209-224.
39. Iyer M.N., He F., Wensel T.G., Mieler W.F., Benz M.S., Holz E.R. Clearance of intravitreal moxifloxacin. Invest. Ophthalmol. Vis. Sci. 2006, 47:317-319.
40. Jarus G., Blumenkranz M., Hernandez E., Sossi N. Clearance of intravitreal fluorouracil. Normal and aphakic vitrectomized eyes. Ophthalmology 1985, 92:91-96.
41. Johnson T.R. Pharmacokinetic and ocular distribution of PF-04523655 and RTP801-inhibiting siRNA, following intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 2010, 51. E-Abstract 2442.
42. Jusko W.J. Guidelines for collection and analysis for pharmacokinetic data. Applied Pharmacokinetics and Applied Therapeutics 2006, 9-26. Lippincott Williams & Wilkins. fourth ed. M.E. Burton (Ed.).
43. Kidron H., del Amo E.M., Vellonen K.S., Urtti A. Prediction of the vitreal half-life of small molecular drug-like compounds. Pharm. Res. 2012, 29:3302-3311.
44. Kidron H., Vellonen K.S., del Amo E.M., Tissari A., Urtti A. Prediction of the corneal permeability of drug-like compounds. Pharm. Res. 2010, 27:1398-1407.
45. Knudsen L.L., Dissing T., Hansen M.N., Nielsen-Kudsk F. Ocular fluorescein kinetics before and after vitrectomy on swine. Graefes Arch. Clin. Exp. Ophthalmol. 2001, 239:832-839.
46. Kontturi L.S., Collin E.C., Murtomaki L., Pandit A.S., Yliperttula M., Urtti A. Encapsulated cells for long-term secretion of soluble VEGF receptor 1: material optimization and simulation of ocular drug response. Eur. J. Pharm. Biopharm. 2014, 10.1016/j.ejpb.2014.10.005.
47. Koyano S., Araie M., Eguchi S. Movement of fluorescein and its glucuronide across retinal pigment epithelium-choroid. Invest. Ophthalmol. Vis. Sci. 1993, 34:531-538.
48. Krohne T.U., Eter N., Holz F.G., Meyer C.H. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am. J. Ophthalmol. 2008, 146:508-512.
49. Krohne T.U., Muether P.S., Stratmann N.K., Holz F.G., Kirchhof B., Meyer C.H., Fauser S. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors. Retina 2015, 35:69-74.
50. Lanevskij K., Japertas P., Didziapetris R., Petrauskas A. Ionization-specific prediction of blood-brain permeability. J.Pharm. Sci. 2009, 98:122-134.
51. Laude A., Tan L.E., Wilson C.G., Lascaratos G., Elashry M., Aslam T., Patton N., Dhillon B. Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. Prog. Retin. Eye Res. 2010, 29:466-475.
52. Lee S.S., Ghosn C., Yu Z., Zacharias L.C., Kao H., Lanni C., Abdelfattah N., Kuppermann B., Csaky K.G., D'Argenio D.Z., Burke J.A., Hughes P.M., Robinson M.R. Vitreous VEGF clearance is increased after vitrectomy. Invest. Ophthalmol. Vis. Sci. 2010, 51:2135-2138.
53. Leeds J.M., Henry S.P., Truong L., Zutshi A., Levin A.A., Kornbrust D. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab. Dispos. 1997, 25:921-926.
54. Levy G. Pharmacologic target-mediated drug disposition. Clin. Pharmacol. Ther. 1994, 56:248-252.
55. Linnankoski J., Makela J.M., Ranta V.P., Urtti A., Yliperttula M. Computational prediction of oral drug absorption based on absorption rate constants in humans. J.Med. Chem. 2006, 49:3674-3681.
56. Liu X., Tu M., Kelly R.S., Chen C., Smith B.J. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab. Dispos. 2004, 32:132-139.
57. Los L.I. The rabbit as an animal model for post-natal vitreous matrix differentiation and degeneration. Eye (Lond) 2008, 22:1223-1232.
58. Mager D.E. Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv. Drug Deliv. Rev. 2006, 58:1326-1356.
59. Mager D.E., Jusko W.J. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J.Pharmacokinet. Pharmacodyn. 2001, 28:507-532.
60. Mandell B.A., Meredith T.A., Aguilar E., el-Massry A., Sawant A., Gardner S. Effects of inflammation and surgery on amikacin levels in the vitreous cavity. Am. J. Ophthalmol. 1993, 115:770-774.
61. Mannermaa E., Reinisalo M., Ranta V.P., Vellonen K.S., Kokki H., Saarikko A., Kaarniranta K., Urtti A. Filter-cultured ARPE-19 cells as outer blood-retinal barrier model. Eur. J. Pharm. Sci. 2010, 40:289-296.
62. Maurice D. Review: practical issues in intravitreal drug delivery. J.Ocul. Pharmacol. Ther. 2001, 17:393-401.
63. Maurice D.M., Mishima S. Ocular pharmacokinetics. Anonymous Pharmacology of the Eye 1984, Springer-Verlag.
64. Meyer C.H., Krohne T.U., Holz F.G. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 2011, 31:1877-1884.
65. Missel P.J. Computer modeling for drug delivery. Ocular Drug Delivery Systems 2012, 59-94. CRC Press, Taylor & Francis group. first ed. D. Thassu, G.J. Chader (Eds.).
66. Mochizuki K., Torisaki M., Yamashita Y., Komatsu M., Tanahashi T. Intravitreal flomoxef sodium in rabbits. Ophthalmic Res. 1993, 25:128-136.
67. Mochizuki K., Yamashita Y., Torisaki M., Komatsu M., Tanahashi T., Kawasaki K. Intraocular kinetics of ceftazidime (Modacin). Ophthalmic Res. 1992, 24:150-154.
68. Moisseiev E., Waisbourd M., Ben-Artsi E., Levinger E., Barak A., Daniels T., Csaky K., Loewenstein A., Barequet I.S. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch. Clin. Exp. Ophthalmol. 2014, 252:331-337.
69. Morlet N., Young S., Naidoo D., Graham G., Coroneo M.T. High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. Br. J. Ophthalmol. 1996, 80:214-216.
70. Nilsson S.F.E., Alm A. Determination of ocular blood flows with the microsphere method. Anonymous Ocular Blood Flow 2012, Springer.
71. Nomoto H., Shiraga F., Kuno N., Kimura E., Fujii S., Shinomiya K., Nugent A.K., Hirooka K., Baba T. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest. Ophthalmol. Vis. Sci. 2009, 50:4807-4813.
72. Obach R.S., Lombardo F., Waters N.J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 2008, 36:1385-1405.
73. Panda-Jonas S., Jonas J.B., Jakobczyk M., Schneider U. Retinal photoreceptor count, retinal surface area, and optic disc size in normal human eyes. Ophthalmology 1994, 101:519-523.
74. Pearson P.A., Hainsworth D.P., Ashton P. Clearance and distribution of ciprofloxacin after intravitreal injection. Retina 1993, 13:326-330.
75. Pflugfelder S.C., Hernandez E., Fliesler S.J., Alvarez J., Pflugfelder M.E., Forster R.K. Intravitreal vancomycin. Retinal toxicity, clearance, and interaction with gentamicin. Arch. Ophthalmol. 1987, 105:831-837.
76. Pitkanen L., Ranta V.P., Moilanen H., Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest. Ophthalmol. Vis. Sci. 2005, 46:641-646.
77. Pitkanen L., Ruponen M., Nieminen J., Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm. Res. 2003, 20:576-583.
78. Quinn R.H., Miller S.S. Ion transport mechanisms in native human retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 1992, 33:3513-3527.
79. Raju B., Thiagarajan G., Das T., Hyderabad Endophthalmitis Research Group Modified high-performance liquid chromatography technique for detection of vancomycin in human vitreous. Ophthalmic Res. 2004, 36:55-61.
80. Reichenbach A., Ziegert M., Schnitzer J., Pritz-Hohmeier S., Schaaf P., Schober W., Schneider H. Development of the rabbit retina. V. The question of 'columnar units'. Brain Res. Dev. Brain Res. 1994, 79:72-84.
81. Roh S., Weiter J.J., Duker J.S. Ocular circulation. Anonymous Duane's Ophthalmology on CD-ROM 2006, Lippincott Williams & Wilkins, pp. (Chapter 5). 2006 ed.
82. Rowe-Rendleman C.L., Durazo S.A., Kompella U.B., Rittenhouse K.D., Di Polo A., Weiner A.L., Grossniklaus H.E., Naash M.I., Lewin A.S., Horsager A., Edelhauser H.F. Drug and gene delivery to the back of the eye: from bench to bedside. Invest. Ophthalmol. Vis. Sci. 2014, 55:2714-2730.
83. Ruby A.J., Williams G.A., Blumenkranz M.S. Vitreous humor. Anonymous 2006, Lippincott Williams & Wilkins.
84. Sanford M. Fluocinolone acetonide intravitreal implant (Iluvien®). Drugs 2013, 73:187-193.
85. Schoenwald R.D. Ocular pharmacokinetics and pharmacodynamics. Ophthalmic Drug Delivery Systems 2003, 135-179. A.K. Mitra (Ed.).
86. Sebag J., Tang M., Brown S., Sadun A.A., Charles M.A. Effects of pentoxifylline on choroidal blood flow in nonproliferative diabetic retinopathy. Angiology 1994, 45:429-433.
87. Severn P.S., Hamilton R. The incidence of serious complications associated with intravitreal therapy in a quaternary ARMD service (2008-2014). Eye (Lond) 2015, 29:150.
88. Shen Y.C., Wang M.Y., Wang C.Y., Tsai T.C., Tsai H.Y., Lee Y.F., Wei L.C. Clearance of intravitreal voriconazole. Invest. Ophthalmol. Vis. Sci. 2007, 48:2238-2241.
89. Stewart M.W., Rosenfeld P.J. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 2008, 92:667-668.
90. Tan L.E., Orilla W., Hughes P.M., Tsai S., Burke J.A., Wilson C.G. Effects of vitreous liquefaction on the intravitreal distribution of sodium fluorescein, fluorescein dextran, and fluorescent microparticles. Invest. Ophthalmol. Vis. Sci. 2011, 52:1111-1118.
91. Taskintuna I., Rahhal F.M., Capparelli E.V., Cundy K.C., Freeman W.R. Intravitreal and plasma cidofovir concentrations after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis. J.Ocul. Pharmacol. Ther. 1998, 14:147-151.
92. Totan Y., Guler E., Guragac F.B. Dexamethasone intravitreal implant for chronic diabetic macular Edema resistant to intravitreal bevacizumab treatment. Curr. Eye Res. 2015, 1-7.
93. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 2006, 58:1131-1135.
94. Vellonen K.S., Malinen M., Mannermaa E., Subrizi A., Toropainen E., Lou Y.R., Kidron H., Yliperttula M., Urtti A. Acritical assessment of invitro tissue models for ADME and drug delivery. J.Control. Release 2014, 190:94-114.
95. Wiederholt M., Kossendrup D., Schulz W., Hoffmann F. Pharmacokinetic of topical cyclosporin A in the rabbit eye. Invest. Ophthalmol. Vis. Sci. 1986, 27:519-524.
96. Wingard L.B., Zuravleff J.J., Doft B.H., Berk L., Rinkoff J. Intraocular distribution of intravitreally administered amphotericin B in normal and vitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 1989, 30:2184-2189.
97. Wu C.D., Müller H.K., Hockwin O., Noll E. Determination of the wet and dry weight of Iris, ciliary body and choroid in man and in different animal species. Ophthalmic Res. 1970, 1:124.
98. Xu J., Heys J.J., Barocas V.H., Randolph T.W. Permeability and diffusion in vitreous humor: implications for drug delivery. Pharm. Res. 2000, 17:664-669.
99. Xu Q., Boylan N.J., Suk J.S., Wang Y., Nance E.A., Yang J., McDonnell P.J., Cone R.A., Duh E.J., Hanes J. Nanoparticle diffusion in, and microrheology of, the bovine vitreous exvivo. J.Control. Release 2013, 167:76-84.
100. Zamudio A.C., Candia O.A. Interaction between mechanical and osmotic forces in the isolated rabbit lens. Exp. Eye Res. 2011, 93:798-803.
101. Zhang K., Zhang L., Weinreb R.N. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat. Rev. Drug Discov. 2012, 11:541-559.
102. Zhu Q., Ziemssen F., Henke-Fahle S., Tatar O., Szurman P., Aisenbrey S., Schneiderhan-Marra N., Xu X., Tubingen Bevacizumab Study Group, Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008, 115:1750-1755. 1755.e1.